NCT06734520 Clinical Study of Super Transplantation in the Treatment of Severe β-thalassemia
| NCT ID | NCT06734520 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Guangzhou Women and Children's Medical Center |
| Condition | Thalassemia Majors (Beta-Thalassemia Major) |
| Study Type | INTERVENTIONAL |
| Enrollment | 3 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2029-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 3 participants in total. It began in 2024-10-01 with a primary completion date of 2029-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single-arm, open label, phase 1 study in subjects with beta-thalassemia. This study will evaluate the safety and efficacy of preconditioning-free super-transplantation on beta-thalassemia pediatric patients.
Eligibility Criteria
Inclusion Criteria: 1. Diagnosis of severe β -thalassemia 2. Age between 7-10 years old, male and female; Weight \< 40kg 3. The patient has or does not have an HLA-compatible or semi-compatible donor, but unconditional transplantation or refusal of blood stem cell transplantation; Patients with thalassemia gene therapy without conditions or refusal; 4. There are fully compatible or incompatible HLA donors, and the physical examination meets the donor conditions; 5. The patient and family members agree to receive hypertransplant therapy and sign a written informed consent prior to the transplant trial. Exclusion Criteria: 1. Mental patients; 2. Participants in other drug clinical trials within the past 1 month; 3. There are no suitable HLA-incompatible donors. 4. Other researchers decide that it is not suitable to participate in this researcher.
Contact & Investigator
Hua Jiang, PHD
STUDY DIRECTOR
Guangzhou Medical University Affiliated Women's and Children's Medical Center
Frequently Asked Questions
Who can join the NCT06734520 clinical trial?
This trial is open to participants of all sexes, aged 7 Years or older, up to 10 Years, studying Thalassemia Majors (Beta-Thalassemia Major). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06734520 currently recruiting?
Yes, NCT06734520 is actively recruiting participants. Contact the research team at jiang_hua18@sina.cn for enrollment information.
Where is the NCT06734520 trial being conducted?
This trial is being conducted at Guangzhou, China, Guangzhou, China.
Who is sponsoring the NCT06734520 clinical trial?
NCT06734520 is sponsored by Guangzhou Women and Children's Medical Center. The principal investigator is Hua Jiang, PHD at Guangzhou Medical University Affiliated Women's and Children's Medical Center. The trial plans to enroll 3 participants.